ArticleScientific reports2025
Identifying diagnostic biomarkers for glaucoma based on transcriptome combined with Mendelian randomization.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Identification and Analysis of Biomarkers Associated With Lipid Metabolism and Ferroptosis in Ulcerative Colitis.Journal of immunology research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Glaucoma poses a significant global health challenge, yet reliable biomarkers for its diagnosis and treatment remain scarce. This study employed Mendelian randomization (MR) and bioinformatics approaches to identify potential biomarkers for glaucoma. Using the GSE9944 dataset, differentially expressed genes (DEGs) were identified and analyzed through protein-protein interaction (PPI) networks and functional enrichment. MR analysis selected DEGs for further evaluation using support vector machine-recursive feature elimination (SVM-RFE), with genes exhibiting high differential expression and an area under the curve (AUC) > 0.7 considered as candidate biomarkers. Among 836 DEGs, the PPI network revealed complex interactions, and functional enrichment highlighted significant involvement of the PI3K-AKT and MAPK signaling pathways. MR analysis linked 113 DEGs to glaucoma, with 57 genes showing consistent expression trends. SVM-RFE identified six signature genes, among which ATP6V0D1 and FAM89B emerged as robust biomarkers (AUC > 0.7). Molecular regulatory network analysis and drug prediction analysis further revealed potential mechanisms and compounds targeting these biomarkers, providing new therapeutic avenues for glaucoma. Experimental validation confirmed that ATP6V0D1 and FAM89B were significantly downregulated under both mechanical and swelling stress conditions, with concurrent suppression of the PI3K/AKT pathway. In conclusion, ATP6V0D1 and FAM89B are promising biomarkers for glaucoma, offering potential applications in diagnosis, treatment, and advancing the understanding of glaucoma pathogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.